3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
5
No longer available
2
Available
2
Approved for marketing
2
Withdrawn
1
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
3
Pheochromocytoma
1
Paraganglioma
1
Neuroblastoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
lutetium Lu 177 dotatate
2
veliparib
1
vandetanib
1
Temozolomide
1
Capecitabine
1
3-fluorobenzylguanidine
1
3-Iodobenzylguanidine
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Pheochromocytoma
×
3-Iodobenzylguanidine
×
Clear all
NCT01941849
2015-12-21
VIBRaNT
University College, London
Phase 1
Withdrawn